在Karen Lynch上周五迅速离职后，西维斯健康 (CVS.US)新任首席执行官David Joyner接任首席执行官一职。华尔街分析师和一些投资者质疑，在安泰医疗保险公司 (Aetna)挣扎于高昂医疗成本之际，Joyner是否具备扭转该公司健康保险业务的合适经验。

David Joyner已成为CVS健康(NYSE:CVS)的新任CEO，在Karen Lynch上周五离职后接任。华尔街分析师和一些投资者对Joyner能否解决困扰Aetna健康保险业务的高医疗成本问题表示担忧。Joyner自2023年起负责CVS的Caremark药房福利管理业务，上周三由董事会任命。 这次领导层变动恰逢CVS撤回2024年盈利预测，并宣布第三季度利润将大幅低于分析师预期，导致 ...

CVS Health announced Friday it has appointed David Joyner as its new Chief Executive Officer, replacing Karen Lynch.

The industry-wide rise in health coverage costs makes the company's Aetna unit the new leader's most difficult problem.

CVS Health CEO Karen Lynch has stepped down and is being replaced by David Joyner amid struggles with rising costs.

Joyner, who heads CVS’s pharmacy-benefit business Caremark, will succeed Karen Lynch.

CVS Health on Friday replaced CEO Karen Lynch with David Joyner, a CVS veteran who retired before returning to the company ...

CVS Health Chief Executive Officer Karen Lynch has stepped down and will be replaced by David Joyner, who runs the company's ...

CVS has replaced CEO Karen Lynch with longtime pharmacy benefits executive David Joyner. The company has been struggling to ...

另外，西维斯健康公布的初步业绩数据显示，第三季度初步调整后 每股收益 为1.05至1.10美元，不及市场预期的1.7美元，取消了2024年的盈利指引，并警告称，“鉴于其医疗保健福利部门的医疗成本压力持续上升”，投资者不要依赖该公司此前的指引。

CVS Health said Friday that as of Thursday David Joyner became its new CEO, replacing Karen Lynch. In an agreement with the ...

Piper Sandler重申了对CVS Health (NYSE:CVS)的增持评级，目标价保持在72.00美元。该公司的立场是在CVS Health宣布2024年第三季度医疗损失率（MLR）和每股收益（EPS）显著低于预期，并撤回2024年全年指引后做出的。为迅速应对这些挑战，CVS Health任命David Joyner为新任首席执行官，即刻生效。